Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai seeks Mexican marketing approval for Belviq
Arena Pharmaceuticals’s internally discovered drug, Belviq, is intended to act as an adjunct to a reduced-calorie diet and high physical activity for chronic weight management in adult patients
Arena Pharmaceuticals’s internally discovered drug, Belviq, is intended to act as an adjunct to a reduced-calorie diet and high physical activity for chronic weight management in adult patients
Relora is a powder used in capsule form for oral administration and alleviates stress, stress-related eating and improves weight management by quieting the hypothalamic-pituitary-adrenal axis without causing drowsiness.
The randomised study with progression free survival (PFS) after 12 weeks as primary endpoint is designed to compare AXL1717 with docetaxel in patients with previously treated, locally advanced
In 2009, the Switzerland based company filed a special leave petition with the highest judicial forum in India. The petition challenged the rejection of the Glivec beta crystal
The safety and delivery of Neo-Kidney Augment product will be assessed in around five patients with advanced chronic kidney disease (CKD) in Phase 1 trial. Tengion president and
The patients who underwent the outpatient transplantation surgery were treated in the third patient cohort of each of the two trials that commenced in July 2011. A 150,000
The investigational recombinant human tripeptidyl peptidase 1, BMN-190, is being developed as a medication for a form of Batten disease called neuronal ceroid lipofuscinosis type 2 (NCL-2). The
The agreement will leverage Ra Pharmaceuticals’ Extreme Diversity platform for the development of peptide-like molecules with antibody diversity and specificity called Cyclomimetics. Ra Pharmaceuticals co-founder, president and CEO
The Court also said that the generic defendants involved in the litigation do not conflict AstraZeneca’s second patent. AstraZeneca North America division executive vice president Paul Hudson said
SmartParts act as the building blocks for the company’s next generation of bioreactor controller systems that have plug-and-play capability and can control any size or type of upstream